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Background:  Coronary  perforation  (CP)  is a  rare, sometimes  lethal  complication  of percutaneous  coronary
intervention  (PCI).
Objectives: The  purpose  of  this  study  was  to review  the  cases  of  CP  and  to investigate  the management
after  CP.
Methods:  A  total  of 3469  PCIs  were  performed  in  our  institution  from  April  1999  to April  2008.  All  CP
cases  were  identiﬁed  from  our  computerized  database.
Results:  Thirty  patients  were  identiﬁed  as  having  CP  (0.86%).  According  to  the  Ellis  classiﬁcation,  we
determined  the  grade  of  perforation  as  type  I  in 17  cases  (56%),  type  II  in  2  cases  (7%),  and  type  III in
11  cases  (37%).  Most  CPs were  caused  by wires  (53%),  while  balloons,  stents,  and  atherectomy  devices
were responsible  for 7%,  37%,  and  3%,  respectively.  Wire  caused  only  1  case  of type  III  CP  (6%),  while
stent  caused  9 type  III CPs  (82%,  p <  0.01).  Four  patients  (36%)  with  type  III  CP  required  urgent  coronary
artery  bypass  graft surgery  (CABG),  while  no  patient  with  type  I/II CP  required  it (p  < 0.01).  Prolonged
balloon  inﬂations  were  effective  for 8 cases  out  of  11  stent  CPs,  however,  the  ballooning  duration  was
signiﬁcantly  longer  than that  in  wire  and  balloon  CP (44  ±  37  min  vs.  21  ± 13  min,  p  < 0.05).
Conclusions:  Stent  CP  often  causes  type  III CP and  one  third  of  type  III CP required  urgent CABG.  Although
stent  CP required  longer  balloon  inﬂations  for the  management,  prolonged  balloon  inﬂation  might  be
useful  for  the  management  even  in  the  stent  CP.
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Coronary perforation (CP) with percutaneous coronary inter-
ention (PCI) occurs only rarely, but sometimes is a lethal
omplication [1–5]. There is no consensus about the optimal treat-
ent of patients with CP; commonly used treatment options
nclude prolonged balloon inﬂation, placement of a covered stent
raft (CSG), pericardiocentesis, or urgent coronary artery bypass
raft (CABG) surgery. CP is one of the indications for emergent
ABG, however, urgent CABG in CP is associated with high mortality
6].
Although the CSG may  be a reliable and highly effective treat-
ent option for sealing CPs complicating PCIs [7],  CSG does not
ave good prognosis in middle-term outcomes [8,9]. Besides, no
tudies about the usefulness of prolonged balloon inﬂation for CP
ave been reported.
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The purpose of this study is to gain information about the inci-
dence, management, and outcome of CP and to investigate the
effectiveness and feasibility of prolonged balloon inﬂation for the
management of CP in the contemporary era.
Materials and methods
Data from all patients who  had CP as a complication of PCI at our
institution from April 1999 to April 2008 were analyzed retrospec-
tively from our computerized database. The type of perforation was
classiﬁed according to the criteria proposed by Ellis et al. [1].  Type
I CP is deﬁned by the development of an extraluminal crater with-
out extravasation, type II CP by a pericardial or myocardial blush
without contrast jet extravasation, and type III CP by extravasation
through a perforation of a cavity spilling into an anatomic cavity. All
patients received dual antiplatelet therapy, aspirin 81–100 mg  and
clopidogrel 75 mg  once a day or aspirin 81–100 mg  once a day and
ticlopidine 200 mg  twice a day orally. Heparin bolus of 100 units/kg
body weight was initially given. Periodic IV bolus of heparin was
also given to keep activated clotting time value between 250 and
350 s throughout the procedure. No GP IIb/IIIa inhibitor was used in
vier Ltd. All rights reserved.
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ur institution. This study was approved by our hospital’s Human
linical Study Committee.
All descriptive data are expressed as the mean ± SD and Stu-
ent’s t-test was used to compare the variables. Categorical
ariables were compared using Fisher’s exact test. A value of p < 0.05
as considered statistically signiﬁcant. All calculations were per-
ormed using SPSS 19 software (SPSS Inc., Chicago, IL, USA).
esults
A total of 3469 interventions were performed at our institution
uring the study period. We  identiﬁed 30 patients with CP (0.86%).
ccording to the Ellis classiﬁcation, we determined the grade of
erforation as type I CP in 17 cases (56%), type II CP in 2 cases (7%),
nd type III CP in 11 cases (37%) as shown in Table 1. No death was
ecorded among these cases in any grade of CP. Most cases of CP
ere caused by wires (16 cases, 53%), while balloons, stents, and
therectomy devices were responsible for 2 cases (7%), 11 cases
37%), and 1 case (3%), respectively. Most cases of wire perforation
ccurred with use of coronary hydrophilic wires (11 cases, 69%)
r stiff wires made for chronic total occlusion (2 cases, 13%). Wire
r balloon caused only 1 case of type III CP cases (6%), while stent
aused 9 cases of type III CP (82%, p < 0.01).
able 1
escription of the coronary perforation cases.
All, N = 30 Type I, N = 17 
Equipment causing the perforation
Wire 16 (53%) 14 (82%)
Balloon 2 (7%) 1 (6%) 
Stent  11 (37%) 2 (12%) 
Atherectomy device 1 (3%) 0 (0%) 
Outcome
Death 0 (0%) 0 (0%)
Tamponade 4 (13%) 2 (12%) 
Treatment
Follow-up only 1 (3%) 1 (6%) 
Ballooning 29 (97%) 16 (94%) 
Ballooning only 22 (73%) 14 (82%) 
Pericardiocentesis 5 (17%) 2 (12%) 
Covered stent 2 (7%) 0 (0%) 
Urgent CABG 4 (13%) 0 (0%) 
ata are expressed as number (percentage).
ABG, coronary artery bypass graft.
Fig. 1. Flow chart of the treatment for coronary perforation. CPs, iology 61 (2013) 206–209 207
A  ﬂow chart of treatment for CP is shown in Fig. 1 according
to the Ellis classiﬁcation. In most CP cases (97%), balloon inﬂations
were performed except in 1 case of type I CP. All patients with
types I and II CP and 64% of patients with type III CP were suc-
cessfully managed by prolonged balloon inﬂation with or without
pericardiocentesis without CABG. Incidences of cardiac tamponade
and pericardiocentesis were 11% (2 cases out of 19) in types I and
II CP and 27% (3 cases out of 11) in type III CP (ns). Seventeen cases
out of nineteen (89%) in patients with types I and II CP were man-
aged only by balloon inﬂation or follow-up, however, 5 cases in
type III CP needed pericardiocentesis or CABG (p < 0.05). Covered
stents were used in 2 cases, however, they could not manage CP
because of unsuccessful delivery (1 case) and inadequate coverage
(1 case) and these 2 CP cases required CABG. CABG was reserved for
those patients who  did not achieve hemostasis with conservative
methods. Four patients (36%) with type III CP required urgent CABG
surgery, while no patient with types I and II CP required it (p < 0.01).
Next, we  compared the prognoses of CP when they were classi-
ﬁed by devices that caused CP as shown in Table 2. While wire,
balloon, and atherectomy CP required only 1 case of CABG out
of 19 CP cases (5%), stent CP required 3 cases of CABG out of
11 CP cases (27%, ns). Incidences of cardiac tamponade, peri-
cardiocentesis, or CABG were 16% (3 cases out of 19) in wire,
Type II, N = 2 Type III, N = 11 p-Value
1 (50%) 1 (9%) 0.000
1 (50%) 0 (0%) 0.131
0 (0%) 9 (82%) 0.000
0 (0%) 1 (9%) 0.433
0 (0%) 0 (0%)
0 (0%) 2 (18%) 1.000
0 (0%) 0 (0%) 1.000
2 (100%) 11 (100%) 1.000
2 (100%) 6 (55%) 0.248
0 (0%) 3 (27%) 0.554
0 (0%) 2 (18%) 0.257
0 (0%) 4 (36%) 0.038
coronary perforations; CABG, coronary artery bypass graft.
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Table 2
The treatment and outcome of coronary perforations.
All, N = 30 Wire, N = 16 Balloon, N = 2 Stent, N = 11 Atherectomy, N = 1 p-Value
Treatment
Follow-up only 1 (3%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 1.000
Ballooning 29 (97%) 15 (94%) 2 (100%) 11 (100%) 1 (100%) 1.000
Ballooning only 22 (73%) 13 (81%) 2 (100%) 7 (64%) 0 (0%) 0.280
Pericardiocentesis 5 (17%) 1 (6%) 0 (0%) 3 (27%) 1 (100%) 0.106
Covered stent 2 (7%) 0 (0%) 0 (0%) 2 (18%) 0 (0%) 0.320
Urgent CABG 4 (13%) 1 (6%) 0 (0%) 3 (27%) 0 (0%) 0.534
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ABG, coronary artery bypass graft.
alloon and atherectomy CP and 27% (4 cases out of 11, ns) in
tent CP.
Prolonged balloon inﬂations were effective for 8 cases out of
1 stent CP cases (73%), while they were effective for 18 cases out
f 19 cases of wire, balloon, and atherectomy device CP (95%, ns).
rolonged balloon inﬂations for the management of CP in most CP
ases (86%) were performed using perfusion balloon to diminish
yocardial ischemia. The ballooning duration for the management
f CP in patients who were managed without CABG in stent CP was
igniﬁcantly longer than that in patients in wire and balloon CP
44 ± 37 min  vs. 21 ± 13 min, p < 0.05). The ballooning duration for
he management of CP in type III CP was also signiﬁcantly longer
han that in types I and II CP (48 ± 37 min  vs. 20 ± 13 min, p < 0.05)
s shown in Fig. 2.
iscussionThe results of the present study series suggest that CP dur-
ng and after PCI was infrequent, however, severe perforation
ometimes required pericardiocentesis or urgent CABG. Most
tent CPs were classiﬁed as type III CP (82%) and often required
ig. 2. Ballooning duration for the management of coronary perforations. (A) Bal-
ooning duration compared between different devices and (B) ballooning duration
ompared between different types of coronary perforations, *p < 0.05; CPs, coronary
erforations.pericardiocentesis or urgent CABG in contrast to wire CP, most
of which were classiﬁed as type I CP (88%) and had good prog-
nosis with only a few additional procedures. Although only a few
papers [1] referred to the ballooning duration for hemostasis, we
showed much longer prolonged balloon inﬂations were effective
and indispensable for the management of severe CP.
We compared groups of patients who  had different grades of
CP according to the Ellis classiﬁcation. Patients who had type I or
II CP had good prognoses with no cases of urgent CABG and only 2
cases of cardiocentesis. It seemed to be unusual that there were
two cases of cardiocentesis in type I perforation. In both cases,
the ﬁrst manifestation of CP was cardiac tamponade, therefore,
and we  performed pericardiocentesis ﬁrst. After the pericardiocen-
tesis, contrast injection showed only extraluminal crater without
extravasation and we considered CP had progressed spontaneously.
In contrast, patients who  had type III CP required 3 cases of
cardiocentesis and 4 cases of urgent CABG. Type III perforations
are obviously associated with higher complication rate including
cardiac tamponade and CABG compared to type I or type II perfo-
rations. The frequency of adverse clinical outcomes relates to the
severity of the CP. More severe perforations were associated with
cardiac tamponade, high morbidity, and mortality as previously
described [1,3,10,11].
In this series, wire perforation was the most common cause
of CP as previously described [12], especially hydrophilic or stiff
wires were responsible for 82% of wire perforations and 43% of all-
cause CPs. The use of stiff extra supported and hydrophilic coronary
guidewires to enable successful transit through the angulated, tor-
tuous, or chronic total occluded lesions has led to an increase in the
occurrence of wire perforations [4,12].  However, most cases of wire
perforation appeared to be type I perforation and managed only
by prolonged balloon inﬂation under the condition of heparin use.
Prolonged balloon inﬂation (average 22 min) seemed to be effec-
tive for the management of wire perforations. Since atherectomy
device caused only one case of CP in this series, the outcome of
atherectomy device was  not conclusive.
In agreement with previous reports [3,13],  this analysis demon-
strated that stent-induced CP resulted in type III CP, which often
required pericardiocentesis, covered stent, and/or urgent CABG.
Besides, the longer ballooning duration in the stent-induced CP
cases, in which only prolonged balloon inﬂation were used for
the hemostasis, was necessary for the management of CP (aver-
age 48 min). Although death was not documented in this series,
stent-induced CP required more than prolonged balloon inﬂation
and might have worse prognosis.
It was  reported that covered stent graft is highly effective in
sealing coronary perforations and the device was successful in
achieving complete closure in most cases of CP [7,14].  In this series,
we used covered stent graft for sealing in 2 CP cases after stent
implantation, however, both cases could not be managed by cov-
ered stent and required urgent CABG. Different from other studies
[3,11,15], we  tried to manage the CP with prolonged balloon inﬂa-
tion. The percentage of covered stent use was  relatively low (18%)
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n type III CP compared to other reports (30–46.2%). Our ﬁndings
id not make an objection to the usefulness of the covered stent
or the nonsurgical treatment of CP. We  used protamine in only
ne case of CP, although protamine is reported to be effective to
top the bleeding from CP by recovering the activating clotting
ime [16]. In some reports, it was reported that administration of
rotamine could cause acute thrombosis [17,18].  We  considered
he risk of acute thrombosis was high and the combination of CP
nd acute thrombosis seemed to be so critical [19,20] that we  did
ot administer protamine in 29 cases. Although there were several
eports describing the usefulness of subcutaneous tissue or auto-
ogus blood clotting for the treatment of CP [21,22], we  did not use
uch techniques in the present study series.
Immediate placement of a perfusion balloon to minimize
schemia [23,24] and sealing in most of the perforations is one
f the appropriate management techniques for CP [1]. Perfusion
alloons were used in 86% of CP cases to complete the prolonged
alloon inﬂations. Type III CP required an average of 48 min  bal-
oon inﬂation time to manage the CP and it was signiﬁcantly longer
han that in type I or type II CP. Type III CP often requires covered
tent or urgent CABG for hemostasis (34–80%) [3,5,11,15],  how-
ver, type III CP in our series required them in only 36% of cases. It
as thought that prolonged balloon inﬂation for CP might be effec-
ive for hemostasis even in the type III CP cases. We  also compared
allooning duration for the management of CP in stent-induced
P and other cases. Stent-induced CP required a longer time to
chieve hemostasis in our series and it was partially because 82%
f stent-induced CPs resulted in type III CP.
imitations
Our study had a number of limitations. Consecutive patients
ho developed CP in a single center were studied retrospectively
n this study. Because CP is a rare complication, our sample size
as relatively low. The relatively low percentage of CPs requires
aution when generalizing the ﬁndings from our study to all cases
f CP. Whether the prospective application of prolonged balloon
nﬂation will result in similar outcomes will require further study.
onclusion
Stent CP often causes type III CP. Types I and II CP had good
rognoses without any cases of urgent CABG surgery. Grade III
P often required urgent CABG surgery, however, no death was
ocumented. Type III CP and stent CP required longer duration of
rolonged balloon inﬂations for the management of CP. Since most
ases of type III and stent CP were managed by prolonged balloon
nﬂations by perfusion balloon, longer prolonged balloon inﬂation
ight be useful for the management of CP.
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